SCHEMBL24988600

SCHEMBL24988600

CCOC(=O)Cc1noc(-c2ccc(Br)cc2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.52
HTT P42858 1/20 0.46
SMPD1 P17405 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 4/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25914344 0.88 NOTUM (0.57) TARBP2HTTSMPD1PPARGPPARD
SCHEMBL25914346 0.88 GAA (0.50) HTTPPARGPPARDPPARASMN1; SMN2
SCHEMBL25381836 0.85 KCNH2 (0.44) TARBP2SMPD1HDAC6SMN1; SMN2MEN1
SCHEMBL1544612 0.79 TRPM8 (0.51) SMPD1PPARGPPARDPPARASMN1; SMN2
SCHEMBL4668238 0.76 RAB9A (0.54) HTTSMPD1HDAC1HDAC8HDAC6
SCHEMBL15919093 0.76 SMN1; SMN2 (0.76) TARBP2HTTPPARGSMN1; SMN2MEN1
SCHEMBL25227460 0.76 SMN1; SMN2 (0.44) TARBP2HTTSMN1; SMN2MEN1KMT2A
SCHEMBL1555 0.75 HTT (0.45) TARBP2HTTSMN1; SMN2MEN1KMT2A
SCHEMBL13422960 0.75 CA12 (0.47) SMN1; SMN2MEN1KMT2AKDM4EALDH1A1
SCHEMBL25914354 0.74 TARBP2 (0.50) TARBP2HTTSMPD1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
EP-4122923-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A TARBP2 4875/4885HTT 2536/4885SMPD1 1925/4885
US-20230265061-A1 OXADIAZOLE DERIVATIVE OXA1L, SCN1A, CACNA1A TARBP2 4875/4885HTT 2536/4885SMPD1 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.